0001209191-20-025491.txt : 20200423
0001209191-20-025491.hdr.sgml : 20200423
20200423201928
ACCESSION NUMBER: 0001209191-20-025491
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200423
FILED AS OF DATE: 20200423
DATE AS OF CHANGE: 20200423
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heyman Richard A.
CENTRAL INDEX KEY: 0001584759
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39269
FILM NUMBER: 20812262
MAIL ADDRESS:
STREET 1: 5871 OBERLIN DRIVE, SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oric Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001796280
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 471787157
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 240 E. GRAND AVE.
STREET 2: 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 388-5600
MAIL ADDRESS:
STREET 1: 240 E. GRAND AVE.
STREET 2: 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-04-23
0
0001796280
Oric Pharmaceuticals, Inc.
ORIC
0001584759
Heyman Richard A.
C/O ORIC PHARMACEUTICALS, INC.
240 E. GRAND AVE., 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
12500
D
Common Stock
165000
I
See footnote
Series A Preferred Stock
Common Stock
62500
I
See footnote
Stock Option (right to buy)
1.60
2028-02-28
Common Stock
46928
D
Stock Option (right to buy)
1.60
2028-06-28
Common Stock
18125
D
The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
The Series A Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
The shares subject to the option are fully vested and immediately exercisable.
The option is subject to an early exercise provision and is immediately exercisable. One fourth (1/4th) of the shares subject to the option vested on May 10, 2019, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
/s/ Dominic Piscitelli, attorney-in-fact
2020-04-23
EX-24.3_911064
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
The undersigned, as a Section 16 reporting person of Oric Pharmaceuticals, Inc.
(the "Company"), hereby constitutes and appoints Jacob Chacko, M.D. and Dominic
Piscitelli, and each of them, as the undersigned's true and lawful
attorney-in-fact to:
1. prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") a Form ID,
including amendments thereto, and any other documents necessary or appropriate
to obtain EDGAR codes and passwords enabling the undersigned to make electronic
filings with the SEC of reports required by Section 16(a) of the Securities
Exchange Act of 1934 or any rule or regulation of the SEC;
2. complete and execute Forms 3, 4 and 5 and other forms and all amendments
thereto as such attorney-in-fact shall in his discretion determine to be
required or advisable pursuant to Section 16 of the Securities Exchange Act of
1934 (as amended) and the rules and regulations promulgated thereunder, or any
successor laws and regulations, as a consequence of the undersigned's ownership,
acquisition or disposition of securities of the Company; and
3. do all acts necessary in order to file such forms with the SEC, any
securities exchange or national association, the Company and such other person
or agency as the attorneys-in-fact shall deem appropriate.
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and
agents shall do or cause to be done by virtue hereof. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934 (as amended).
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 23rd day of April, 2020.
Signature: /s/ Richard Heyman
Print Name: Richard Heyman